Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
French clinical-stage biotech Abivax has released positive Phase IIb clinical induction and preliminary maintenance study results. 254 patients with moderate to severe ulcerative colitis (UC) were treated with ABX464, a small molecule for once-daily administration with a first-in-class mechanism of action. 26 May 2021
Biotechnology
Shares in New Jersey, USA-based company Provention Bio rose by over a quarter on Tuesday, after the firm announced positive regulatory news related to its type 1 diabetes (T1D) candidate teplizumab. 26 May 2021
Biotechnology
Ysios Capital, Spain’s largest and leading European venture capital firm specialized in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million euros ($260 million). 26 May 2021
Biotechnology
The European Commission (EC) should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines. 26 May 2021
Biotechnology
The US Food and Drug Administration has accepted the Biologics License Application (BLA) for ublituximab, an investigational glycoengineered anti-CD20 monoclonal antibody, in combination with Ukoniq (umbralisib), TG Therapeutics’ once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). 26 May 2021
Biotechnology
Shares in US biotech Pieris Pharmaceuticals rocketed by nearly 50% in three hours of trading on Tuesday on news of a multi-program research collaboration and license agreement with the Roche subsidiary Genentech. 25 May 2021
Biotechnology
US pharma major Merck & Co’s presentations at this year’s ASCO annual meeting will focus primarily on three products. 25 May 2021
Biotechnology
Positive top-line results have been reported from the Phase III PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment naïve. 25 May 2021
Biotechnology
American messenger RNA specialist Moderna has announced positive results from a study of its COVID-19 vaccine (mRNA-1273) in adolescents. 25 May 2021
Biotechnology
Norwegian natural killer cell specialist Zelluna Immunotherapy has entered into two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. 25 May 2021
Biotechnology
Johnson & Johnson subsidiary Janssen has received approval from the European Commission for Ponvory (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features. 25 May 2021
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Verastem’s investigational RAF/MEK inhibitor VS-6766, combined with defactinib, its FAK inhibitor, in recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. 25 May 2021
Biotechnology
A new report from industry analyst GlobalData finds that the global biotech industry is experiencing a shortage of viral vectors, an essential component of advanced therapies. 25 May 2021
Biotechnology
Shares of US biotech NGM Biopharmaceuticals closed down more than 40% at $16.81 yesterday, after it revealed a major disappointment with its aldafermin in the treatment of non-alcoholic steatohepatitis (NASH), joining a string of failures in this therapy area. 25 May 2021
Biotechnology
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai’s Junshi Biosciences to shine. 25 May 2021
Biotechnology
Swiss pharma giant Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 ASCO Annual Meeting. 25 May 2021
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for Boehringer Ingelheim’s BI 425809 for the treatment of cognitive impairment associated with schizophrenia (CIAS). 24 May 2021
Biotechnology
The Indian subsidiary of Swiss pharma major Roche and domestic drugmaker Cipla Limited today announced that the first batch of the Roche antibody cocktail (casirivimab and imdevimab) is now available in India, while a second batch will be made available by mid-June. 24 May 2021
Biotechnology
Real-world evidence from public health authorities in the UK suggests that coronavirus vaccines from Pfizer and BioNTech, and AstraZeneca, are effective against the so-called Indian variant. 24 May 2021
Biotechnology
Last Saturday, US biotech Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved the company’s application for conditional marketing authorization for its mRNA vaccine against COVID-19. 24 May 2021
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze